Elite in Mixed Connective Tissue Disease

Marzena H. Olesinska

Warsaw, MZ, PL 
Elite in Mixed Connective Tissue Disease
Warsaw, MZ, PL 
OverviewLocationsClinical Research

Overview

Marzena Olesinska practices in Warsaw, Poland. Ms. Olesinska is rated as an Elite expert by MediFind in the treatment of Mixed Connective Tissue Disease. Her top areas of expertise are Mixed Connective Tissue Disease, Systemic Lupus Erythematosus (SLE), Scleroderma, Systemic Sclerosis (SSc), and Synovectomy.

Her clinical research consists of co-authoring 102 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 14 articles in the study of Mixed Connective Tissue Disease.

Gender
Female

Locations

Warsaw, MZ 02637, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
View 1 Less Clinical Trial

102 Total Publications

Damage Burden in Polish Patients with Antiphospholipid Syndrome Measured Using Damage Index for Antiphospholipid Syndrome (DIAPS).
Damage Burden in Polish Patients with Antiphospholipid Syndrome Measured Using Damage Index for Antiphospholipid Syndrome (DIAPS).
Journal: Biomedicines
Published: April 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Olesinska's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile